Evidence map›Paper›PMID 28067384›Full record

ReviewNanoscale2017

Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.

Mahdi Karimi, Parham Sahandi Zangabad, Fatemeh Mehdizadeh, Hedieh Malekzad, Alireza Ghasemi, Sajad Bahrami, Hossein Zare, Mohsen Moghoofei, Amin Hekmatmanesh, Michael R Hamblin

Open access · greenAbstract readReview
In one paragraph

Review in Nanoscale, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 149 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Cucurbit[8]uril-based supramolecular theranostics.Journal of nanobiotechnology · 2024
    Review
  11. Article
  12. The Next Generation of Drug Delivery: Harnessing the Power of Bacteriophages.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Mahdi Karimi *Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Parham Sahandi Zangabad *Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz University of Medical Science (TUOMS), Tabriz, Iran.
Fatemeh MehdizadehDepartment of Applied Chemistry, University of Tabriz, Tabriz, Iran.
Hedieh MalekzadAdvanced Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran.
Alireza GhasemiDepartment of Materials Science and Engineering, Sharif University of Technology, 11365-9466, Tehran, Iran.
Sajad BahramiDepartment of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hossein ZareBiomaterials Group, Materials Science & Engineering Department, Iran University of Science & Technology, P.O. Box 1684613114 Tehran, Iran.
Mohsen MoghoofeiDepartment of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Amin HekmatmaneshLaboratory of Intelligent Machines, Lappeenranta University of Technology, 53810, Finland.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
Iran University of Medical Sciences · IRHarvard–MIT Division of Health Sciences and Technology · USIran University of Science and Technology · IRLappeenranta-Lahti University of Technology · FISharif University of Technology · IRTabriz University of Medical Sciences · IRUniversity of Tabriz · IR

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

Nanocages (NCs) have emerged as a new class of drug-carriers, with a wide range of possibilities in multi-modality medical treatments and theranostics. Nanocages can overcome such limitations as high toxicity caused by anti-cancer chemotherapy or by the nanocarrier itself, due to their unique characteristics. These properties consist of: (1) a high loading-capacity (spacious interior); (2) a porous structure (analogous to openings between the bars of the cage); (3) enabling smart release (a key to unlock the cage); and (4) a low likelihood of unfavorable immune responses (the outside of the cage is safe). In this review, we cover different classes of NC structures such as virus-like particles (VLPs), protein NCs, DNA NCs, supramolecular nanosystems, hybrid metal-organic NCs, gold NCs, carbon-based NCs and silica NCs. Moreover, NC-assisted drug delivery including modification methods, drug immobilization, active targeting, and stimulus-responsive release mechanisms are discussed, highlighting the advantages, disadvantages and challenges. Finally, translation of NCs into clinical applications, and an up-to-date assessment of the nanotoxicology considerations of NCs are presented.

Indexed as

Drug Delivery SystemsTheranostic NanomedicineAnimalsBiocompatible MaterialsDrug-Related Side Effects and Adverse ReactionsGoldHumansNanostructuresNeoplasmsBiocompatible MaterialsGold

Identifiers

PMID28067384
PMCPMC5300024
OpenAlexW2560353251

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.